Short stature is the most ubiquitous feature of Turner syndrome (TS). Today, many girls with TS are treated with recombinant human growth hormone (GH) to accelerate growth in childhood and to improve adult height. Here, we will review the history of our understanding of growth in TS, reflect on the path of clinical trials ultimately leading to regulatory approval for clinical use of GH, discuss factors associated with growth outcomes and survey the current unanswered questions about growth and GH in TS.
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| INTRODUCTION
Growth failure and reduced adult height affect 95-100% of girls and women with Turner syndrome (TS) (Gravholt et al., 2017) . Supplemental growth hormone (GH) increases final height and is commonly used when TS is diagnosed prior to epiphyseal fusion. In this review, we examine the historical paths leading to regulatory approval of GH, non-GH treatments and other factors affecting growth in TS, and evaluate current recommendations for GH therapy as well as remaining questions and possible future directions.
| THE HISTORY OF OUR UNDERSTANDING OF GROWTH IN TURNER SYNDROME
In Henry Turner's initial report at the 1938 Meeting for the Study of Internal Secretions in San Francisco, he described a syndrome of infantilism, congenital webbing of the neck and cubitus valgus in seven subjects; interestingly, short stature did not even enter into the title, although it was a feature shared by all of the patients in his report (Turner, 1938) . We know from subsequent studies, however, that reduced height affects nearly all of the TS population.
Mean birth length in TS is between the 10th% and 25th% (Davenport et al., 2002) , suggesting some element of fetal growth retardation (FitzSimmons, Fantel, & Shepard, 1994; Wisniewski, Milde, Stupnicki, & Szufladowicz-Wozniak, 2007) . There is, however, no demonstrable decrease or abnormality of the prenatal GH-IGF axis (Ducos et al., 2001 ). Postnatal growth is blunted, such that threequarters of TS girls fall below the 5th percentile of height by age 3.5 years. Schoolage girls demonstrate slower than average growth, with the difference in height between affected and unaffected girls increasing over the course of childhood and exacerbated by the lack of a full pubertal growth spurt (Lyon, Preece, & Grant, 1985) . Mean adult height averages 20 cm below the population normal height, with natural history studies citing final heights around 142-144 cm (4 0 8.5 00 ) (Ranke & Grauer, 1994 ).
Short stature in TS is not due to hormonal deficiencies, but is better thought of as a skeletal dysplasia. The skeletal differences in the cranium, sternum, upper and lower extremities, spine and feet are well documented (Gravholt et al., 2017; Ogata, 2002) . The SHOX (short stature homeobox gene located on the X and Y chromosomes) gene regulates chondrocyte differentiation and maturation and its deficiency is likely the major contributor to the skeletal dysplasia in TS, though additional genes from the short arm of the X-chromosome may also be involved. Those with isolated SHOX gene deficiency and TS have similar responses to GH treatment, but in neither condition does GH correct the underlying skeletal defects (Blum et al., 2013) .
In addition to stimulating linear bone growth, GH increases bone mass, acts on adipose tissue to promote favorable lipid and glucose metabolism, and on muscle to increase amino acid transport. GH binds to its receptor in the liver and cartilage leading to production of IGF-1, which through endocrine and paracrine/autocrine mechanisms then stimulates linear bone growth. GH also acts at the epiphysis to promote prechondrocyte differentiation and osteoblast expansion. Both GH and IGF-1 are necessary for normal linear growth though exact cellular targets for GH are not entirely clear in complex tissues such as the growth plate (Reh & Geffner, 2010) .
In TS, a detailed study of GH secretion demonstrated that although GH secretion (both GH reserve and mean spontaneous nocturnal secretion) is abnormal, it did not influence height in TS patients.
Therefore, GH stimulation testing is considered unnecessary (Cavallo & Gurrado, 1999) and highlights that although lack of GH may not be the cause of short stature in TS, the addition of GH may be quite beneficial in correcting the growth deficit.
| DEVELOPING A CASE FOR THE USE OF GROWTH HORMONE IN TS
The first documented use of "growth hormone" in TS was in Henry
Turner's original publication (Turner, 1938) . Reportedly, in one patient, "anterior pituitary growth hormone, 2 cc. 3 times weekly was prescribed, and injections were continued for approximately 5 months without any appreciable increase in her height" (Turner, 1938) . Certainly this was not recombinant GH or even human GH, which was not available at that
time; yet this pronouncement promoted the belief that remained for decades; that GH was not effective in conditions such as TS.
Initial purification of scarce quantities of human GH from pituitary Two pivotal studies ultimately paved the road for regulatory approval for the clinical use of GH in TS.
The first was a study of 70 girls treated to adult height with interim analyses published after 1, 3 and 6 years of treatment (Rosenfeld et al., 1986 (Rosenfeld et al., , 1988 (Rosenfeld et al., , 1992 (Rosenfeld et al., , 1998 . Treatment with GH, oxandrolone, or the combination of GH + oxandrolone was compared to an untreated group.
After an initial phase of 12-24 months, the group receiving GH alone or GH + oxandrolone continued the same treatment, while the other two groups switched to a combination of GH plus oxandrolone. In the data submitted to the FDA, only one girl in the group receiving GH alone did not reach the 50th percentile for TS. About half of the girls were above the 90th percentile of the growth curve for TS. The combination therapy was even more impressive, bringing many girls well into the normal growth curve (Figure 1 ) (Rosenfeld et al., 1998) . The investigators found the results compelling, but the FDA desired an additional controlled trial to adult height to be sure the response was clinically meaningful.
The second study was designed to be a randomized controlled trial to adult height (Stephure, 2005) , with all 154 subjects receiving sex steroid replacement at age 13 and followed to protocol completion, defined as height velocity less than 2 cm/yr and bone age ≥ 14 yr.
Unfortunately, there was a high dropout rate in the study, particularly in the control group, as parents could see their daughters were growing poorly and understandably were reluctant to forgo possible GH treatment, thereby making statistical analysis of the study findings problematic.
The results were still clear enough: those in the treatment arm grew an additional 7-7.5 cm above the control arm. This was the first evidence from a randomized controlled study to adult height, showing that GH was effective and confirming the findings from the studies by Rosenfeld et al.
The interim analysis was submitted to regulatory agencies for review.
Independently, these two studies would probably not have been sufficient to the FDA, but together they proved convincing and in 1996 recombinant GH use was approved for use in TS. Natural history data would prove invaluable in assessing the results from these and subsequent studies and eventually would help convince regulatory agencies that robust natural-history studies could be used as an alternative or adjunct to placebo-controlled studies to final height in conditions such as Noonan syndrome and others (Osio, Dahlgren, Wikland, & Westphal, 2005) .
A study in the Netherlands tested the effect of higher doses of GH on height (Sas et al., 1999) . 
| FACTORS AFFECTING GROWTH OUTCOMES IN TS
The effect of recombinant GH on final height is influenced by overall GH exposure (total treatment duration, age at initiation, duration of treatment prior to puberty, GH dosage). Unmodifiable factors intrinsic to the girl and her family (patient height at treatment start, midparental target height) are also predictive and important for understanding realistic treatment outcomes (Hofman et al., 1997; Quigley, Crowe, Anglin, & Chipman, 2002; Ranke et al., 2000; Reiter, Blethen, Baptista, & Price, 2001; Sas et al., 1999; van Pareren et al., 2003) .
Current clinical practice guidelines (Gravholt et al., 2017) nicely summarize the side effects and adverse events specific to the use of GH in TS apparent in observational studies, specifically addressing concerns for intracranial hypertension, slipped capital femoral epiphysis, scoliosis and possibly altered glucose tolerance. There is also generally reassuring data for GH's impact in TS on blood pressure, risk factors for cardiovascular disease, body composition, and prevalence of otitis media and hearing loss.
Interruptions in GH treatment likely negatively impact overall effectiveness, though studies of the effect of compliance have not been reported. Our own experience suggests insurance changes, physician access, patient geographic relocation, injection device failure, and medication adherence are likely to reduce the overall growth benefit compared to clinical trials in which medication is available under optimal conditions.
As overall height gains with GH seem to be on the order of 1-2 cm per year of treatment (Gravholt et al., 2017) , beginning therapy as early as possible (prior to age 4 for most girls), and ideally before there is already significant short stature, allows for height to remain relatively on track with peers, and ultimately permits estrogen replacement at an age-appropriate time. Indeed, early GH treatment may correct growth failure and normalize height in infants and toddlers with TS (Davenport et al., 2007) and studies of higher doses of GH to adult height have permitted near-normalization of final height (mean around 25th% of unaffected women) (Sas et al., 1999) . Alternatively, as not all girls with TS demonstrate early growth failure, initiating GH therapy once the child drops below the 5th percentile is also a reasonable approach.
However, when the diagnosis of TS is not known, height is often severely impacted before the underlying condition is discovered and only a limited time for GH treatment remains. Rates of delayed diagnosis vary by region and have changed as awareness and availability of prenatal testing have changed, though in one case series, girls were diagnosed on average 5 years after height fell below the 5th% and compared to girls with 45, X karyotype, those with mosacisim were more likely to have delayed diagnosis (Massa et al., 2005) . Since girls with growth failure tend to be underdiagnosed relative to boys, it is important to emphasize that every girl with growth failure warrants evaluation (Grimberg, Kutilov, & Cucchiara, 2005) .
| GROWTH BEYOND GROWTH HORMONE
The addition of the anabolic steroid oxandrolone has been studied for decades. Oxandrolone offers modest synergistic effect with GH in short-term height velocity as well as final height attainment (Zeger et al., 2011) , with overall addition of 2-5 cm of final height. Current guidelines (Gravholt et al., 2017) suggest consideration of oxandrolone starting at age 10 if the diagnosis of TS (and thereby the initiation of GH) was delayed and adult height is predicted to be unsatisfactory.
However the unwanted effects of delayed breast development, and dose-dependent virilization may be undesirable.
There may be some synergistic effect on height of early (prepubertal age) ultra-low dose estrogen replacement when added to growth hormone (Quigley et al., 2014; Ross et al., 2011) , as well as benefits to the lipid profile (Ruszala et al., 2017) , but current guidelines do not recommend this, as dosing has not been optimized and long-term safety not assessed.
Current clinical practice guidelines acknowledge the optimal estrogen replacement therapy regimen to induce pubertal development is still being evaluated, though recommends starting treatment between 11 and 12 years of age and increasing to adult dosing over 2-3 years. Transdermal replacement is preferred with dosing beginning at 3-7 μg/day and increasing gradually to 25-100 μg/day based on clinical response (Gravholt et al., 2017) .
Age-appropriate estrogen replacement is ideal, although timing of pubertal induction must be individualized based on patient priorities, such as optimal height attainment. Therefore, early diagnosis and GH treatment offer the best chance to prevent both significant short stature and delayed pubertal development.
Other health factors may have their own impact on height attainment and require ongoing assessment. A delayed diagnosis of hypothyroidism has a significant effect on final height (Rivkees, Bode, & Crawford, 1988) . Celiac disease may result in delayed growth until diagnosed and appropriately treated often permitting complete catchup growth (Damen, Boersma, Wit, & Heymans, 1994; Meazza et al., 2009) . In congenital cardiac disease, growth may affect cardiac outcome or vice versa (Costello et al., 2015; Heye et al., 2019) . Ultimately, the complex interplay of health factors, whether associated with TS or not, will influence the individual response to GH treatment.
Future therapies being developed to augment height may someday have a role in the treatment of short stature in TS. Long-acting GH formulations, which may improve adherence to therapy, are being studied in patients with GH deficiency and have been slow to come to market (Lal & Hoffman, 2018) ; however no studies have included patients with TS. A C-natriuretic peptide analog affecting the FGFR3 pathway (a target of the transcription factor SHOX [Decker et al., 2011] ) is currently being explored for children with achondroplasia (Legeai-Mallet, 2016) but has not yet been explored in those with SHOX deficiency, such as in TS.
6 | WHERE DO WE GO FROM HERE?
When GH was approved for use in TS over 20 years ago, there were questions about the ideal age for initiation, ideal dosage and regimen, duration of treatment, the role of anabolic steroids, optimal age of estrogen replacement so as to best normalize puberty without compromising growth, how to optimize compliance, as well as the impact of therapy on psychosocial function, and potential complications of GH treatment specific to TS (Rosenfeld, 1997) . While data addressing these issues have been accumulated, important challenges remain such as the importance of early diagnosis and the significance of optimal adherence to therapy.
The pioneering studies of the use of GH in TS established the effectiveness of treatment. A timely diagnosis is nevertheless still required in order to initiate GH therapy early in childhood, so as to optimize age-appropriate linear growth and allow for pubertal induction based on the patient's priorities, balancing optimal growth with optimal timing of puberty. 
